Swiss Chemicals Stock News

Sandoz Group (SWX:SDZ) is back in focus after the European Commission granted marketing authorization for Ondibta, a biosimilar insulin glargine that could widen diabetes treatment options across Europe from early 2027. See our latest analysis for Sandoz Group. The Ondibta news lands after a strong 90 day share price return of 27.17% and a 1 year total shareholder return of 49.84%, suggesting momentum has been building around Sandoz Group, despite a 1 day share price return decline of 0.75%...

With a price-to-earnings (or "P/E") ratio of 38.5x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...

The Ascom Holding AG ( VTX:ASCN ) share price has done very well over the last month, posting an excellent gain of 32...

UBS Group (SWX:UBSG) is reviewing potential successors to CEO Sergio Ermotti as he prepares to step down around 2026 or 2027. Ermotti is being considered for a possible move to chairman after a cooling off period, subject to governance requirements. The bank reports that work to integrate Credit Suisse is close to completion, following its acquisition of the rival group. UBS Group is a global wealth manager and investment bank, and the combination with Credit Suisse is one of the largest...

Why the Geneva and Palm Beach airport projects matter for Avolta (SWX:AVOL) Avolta (SWX:AVOL) is in focus after announcing a multi-year redevelopment of its food and beverage footprint at Geneva Airport, alongside two 10-year contracts to expand travel retail and dining at Palm Beach International Airport. Together, these projects highlight how the company is leaning into long-duration airport concessions, refreshed concepts, and a broader mix of proprietary and local brands, giving investors...

Helvetia Baloise Holding (VTX:HBAN) has had a rough month with its share price down 3.7%. But if you pay close...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...

It's not a stretch to say that Swiss Life Holding AG's ( VTX:SLHN ) price-to-earnings (or "P/E") ratio of 20.8x right...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...

It hasn't been the best quarter for TX Group AG ( VTX:TXGN ) shareholders, since the share price has fallen 15% in that...

Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...

While not a mind-blowing move, it is good to see that the Temenos AG ( VTX:TEMN ) share price has gained 23% in the...

Let's talk about the popular Kuehne + Nagel International AG ( VTX:KNIN ). The company's shares saw a significant share...

As the European market shows resilience with the STOXX Europe 600 Index rising by 0.77% amid solid economic data and earnings results, investors are increasingly focusing on dividend stocks to bolster their portfolios. In a climate where stability and income generation are highly valued, selecting dividend stocks that align with robust financial performance and consistent payout histories can be a prudent strategy for enhancing investment portfolios.

Schindler Holding AG ( VTX:SCHN ) saw a double-digit share price rise of over 10% in the past couple of months on the...

In January 2026, VAT Group AG reported preliminary results showing fourth-quarter 2025 net sales of CHF 257 million versus CHF 283.2 million a year earlier, and full-year 2025 net sales of CHF 1.07 billion compared with CHF 942.2 million. Despite the softer quarterly sales, fourth-quarter 2025 orders climbed to about CHF 305 million, rising both sequentially and year on year, highlighting a renewed pickup in demand that contrasts with the more muted full-year order trend. We will now...

Sika (SWX:SIKA) is back in focus after its 2025 trading update showed weaker sales, a lower profit margin outlook, and a sharp share price reaction as investors reassess regional and currency risks. See our latest analysis for Sika. The recent 2025 trading update and guidance cut come on top of a weaker share price trend, with a 90 day share price return of 14.17% and a 1 year total shareholder return of 32.05%. This points to fading momentum as investors reassess regional and currency...

Asmallworld AG ( VTX:ASWN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

ARYZTA AG's ( VTX:ARYN ) price-to-earnings (or "P/E") ratio of 12.8x might make it look like a buy right now compared...

Despite an already strong run, Comet Holding AG ( VTX:COTN ) shares have been powering on, with a gain of 33% in the...

Why Roche Holding (SWX:ROG) is on investors’ radar today Roche Holding (SWX:ROG) is drawing attention after recent share price moves, with the stock last closing at CHF 348.90 and showing double digit returns over the past month and past 3 months. For investors, that combination of recent performance and the company’s sizeable pharmaceuticals and diagnostics footprint raises the question of how the current price lines up with its fundamentals and value characteristics. See our latest analysis...

Recent performance snapshot Nestlé (SWX:NESN) has been under pressure recently, with the share price showing a 1-day decline of 1.67% and a roughly 5% decline over the past month. See our latest analysis for Nestlé. At a share price of CHF75.24, Nestlé’s recent 30-day share price decline of about 5% and 90-day share price decline of about 11% contrast with a 1-year total shareholder return of roughly 5%. This suggests that near term momentum is fading while longer term returns remain...

In mid-January 2026, Galderma presented new clinical data on its neuromodulator portfolio Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid, alongside a dedicated Relfydess Masterclass led by expert physicians and its Global Head of R&D. The strong responder rates, extended median time to baseline, and head-to-head diffusion data for Relfydess highlighted scientific differentiation that Galderma is using to reinforce its position in injectable aesthetics. We’ll now...